Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.

MLA

Asleh, Rabea, et al. “Timing of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor Initiation and Allograft Vasculopathy Progression and Outcomes in Heart Transplant Recipients.” ESC Heart Failure, vol. 5, no. 6, Dec. 2018, pp. 1118–29. EBSCOhost, https://doi.org/10.1002/ehf2.12329.

APA

Asleh, R., Briasoulis, A., Pereira, N. L., Boilson, B. A., Edwards, B. S., Adigun, R., Maltais, S., Daly, R. C., Lerman, A., & Kushwaha, S. S. (2018). Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients. ESC Heart Failure, 5(6), 1118–1129. https://doi.org/10.1002/ehf2.12329

Chicago

Asleh, Rabea, Alexandros Briasoulis, Naveen L Pereira, Barry A Boilson, Brooks S Edwards, Rosalyn Adigun, Simon Maltais, Richard C Daly, Amir Lerman, and Sudhir S Kushwaha. 2018. “Timing of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor Initiation and Allograft Vasculopathy Progression and Outcomes in Heart Transplant Recipients.” ESC Heart Failure 5 (6): 1118–29. doi:10.1002/ehf2.12329.